IRVINE, Calif.--(BUSINESS WIRE)--Ivantis announced the enrollment of the first patient in the Hydrus IV study today. The HydrusTM Microstent is the world’s first intracanalicular (“in the canal”) scaffold for treatment of primary open angle glaucoma, a disease that afflicts over 70 million people worldwide and approximately 3 million people in the United States. The HYDRUS IV Study will include patients with glaucoma who are undergoing cataract surgery and also taking eye drop medication for their glaucoma. Per the study design, patients will either receive cataract surgery alone or cataract surgery plus the Hydrus Microstent. While the first phase of the study is intended to initially analyze results from a smaller number of patients, it is anticipated that more than 500 patients in over 25 centers globally will ultimately be included.
